
Rafael Renatino Canevarolo

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6569589/publications.pdf

Version: 2024-02-01



#	Article	IF	CITATIONS
1	Cytotoxic 3,4,5-trimethoxychalcones as mitotic arresters and cell migration inhibitors. European Journal of Medicinal Chemistry, 2013, 63, 501-510.	2.6	58
2	Metabolic time-course response after resistance exercise: A metabolomics approach. Journal of Sports Sciences, 2017, 35, 1211-1218.	1.0	47
3	N-(1′-naphthyl)-3,4,5-trimethoxybenzohydrazide as microtubule destabilizer: Synthesis, cytotoxicity, inhibition of cell migration and inÂvivo activity against acute lymphoblastic leukemia. European Journal of Medicinal Chemistry, 2015, 96, 504-518.	2.6	33
4	Leucine-rich diet alters the 1H-NMR based metabolomic profile without changing the Walker-256 tumour mass in rats. BMC Cancer, 2016, 16, 764.	1.1	28
5	A pharmacodynamic model of clinical synergy in multiple myeloma. EBioMedicine, 2020, 54, 102716.	2.7	20
6	Integrative analysis to select cancer candidate biomarkers to targeted validation. Oncotarget, 2015, 6, 43635-43652.	0.8	18
7	Photocatalytic and Cytotoxic Effects of Nitrogen-Doped TiO ₂ Nanoparticles on Melanoma Cells. Journal of Nanoscience and Nanotechnology, 2018, 18, 3722-3728.	0.9	17
8	Leucine-Rich Diet Modulates the Metabolomic and Proteomic Profile of Skeletal Muscle during Cancer Cachexia. Cancers, 2020, 12, 1880.	1.7	17
9	Analysis and characterisation of bovine oocyte and embryo biomarkers by matrix-assisted desorption ionisation mass spectrometry imaging. Reproduction, Fertility and Development, 2016, 28, 293.	0.1	15
10	Early metabolic response after resistance exercise with blood flow restriction in well-trained men: a metabolomics approach. Applied Physiology, Nutrition and Metabolism, 2018, 43, 240-246.	0.9	15
11	Metabolomic characterization of renal ischemia and reperfusion in a swine model. Life Sciences, 2016, 156, 57-67.	2.0	14
12	IAP and HDAC inhibitors interact synergistically in myeloma cells through noncanonical NF-κB– and caspase-8–dependent mechanisms. Blood Advances, 2021, 5, 3776-3788.	2.5	10
13	Plasma cell dependence on histone/protein deacetylase 11 reveals a therapeutic target in multiple myeloma. JCl Insight, 2021, 6, .	2.3	8
14	Xanthan Gum Removal for 1H-NMR Analysis of the Intracellular Metabolome of the Bacteria Xanthomonas axonopodis pv. citri 306. Metabolites, 2014, 4, 218-231.	1.3	5
15	Structural Basis of Colchicine-Site targeting Acylhydrazones active against Multidrug-Resistant Acute Lymphoblastic Leukemia. IScience, 2019, 21, 95-109.	1.9	4
16	Aerobic training prevents cardiometabolic changes triggered by myocardial infarction in ovariectomized rats. Journal of Cellular Physiology, 2021, 236, 1105-1115.	2.0	2
17	Pharmacodynamical Modeling of Two-Way Synergistic Effect for High-Throughput Drug Combination Screening in an Ex Vivo Reconstruction of Bone Marrow Using Primary Multiple Myeloma Cells. Blood, 2018, 132, 1919-1919.	0.6	2
18	Ex Vivo Drug Sensitivity and Functional Genomics Platform Identifies Novel Combinations Targeting Intrinsic and Extrinsic Apoptotic Signaling Pathways in Multiple Myeloma. Blood, 2020, 136, 49-50.	0.6	2

#	Article	IF	CITATIONS
19	CancerCellTracker: a brightfield time-lapse microscopy framework for cancer drug sensitivity estimation. Bioinformatics, 2022, 38, 4002-4010.	1.8	2
20	Characterization of Synergistic Selinexor Combinations of Dexamethasone, Pomalidomide, Elotuzumab and Daratumumab in Primary MM Samples Ex Vivo. Blood, 2020, 136, 29-30.	0.6	1
21	Addendum: Cruz, B., et al. Leucine-Rich Diet Modulates the Metabolomic and Proteomic Profile of Skeletal Muscle during Cancer Cachexia. Cancers 2020, 12, 1880. Cancers, 2021, 13, 880.	1.7	0
22	Abstract 1061: Characterization of synergistic selinexor combinations with dexamethasone, pomalidomide, elotuzumab, and daratumumab in primary MM cells. , 2021, , .		0
23	Semi-quantification and elucidation of bovine embryo biomarkers by mass spectrometry imaging. Reproduction Abstracts, 0, , .	0.0	0
24	A Systems Biology Approach to Identify Mechanisms of Therapy Resistance in Multiple Myeloma. Blood, 2018, 132, 3266-3266.	0.6	0
25	Systems Biology Analysis Identifies Targetable Vulnerability Networks to Proteasome Inhibitors in Multiple Myeloma. Blood, 2018, 132, 950-950.	0.6	0
26	Integrated Multi-Level Omics to Characterize Bortezomib Resistance in Multiple Myeloma. Blood, 2019, 134, 5534-5534.	0.6	0
27	Re-Constructing and Exploiting Transcriptional Regulatory Networks in Multiple Myeloma Drug Resistance. Blood, 2019, 134, 5544-5544.	0.6	0
28	Dynamic Epigenetic Landscapes Define Multiple Myeloma Progression and Drug Resistance. Blood, 2020, 136, 32-33.	0.6	0